Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

241.19
+5.922.52%
Volume:2.83M
Turnover:677.38M
Market Cap:581.10B
PE:21.87
High:241.45
Open:236.80
Low:235.75
Close:235.27
52wk High:251.71
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.51
T/O Rate:0.12%
Dividend:5.14
Dividend Rate:2.13%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:7.13
PE(LYR):21.86

Loading ...

US FDA - Approves Tec-Dara for Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
Mar 06

United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says

MT Newswires Live
·
Mar 06

Dow's 400-Point Fall Led By Losses In Shares Of Walmart, Merck

Dow Jones
·
Mar 05

Johnson & Johnson price target raised to $250 from $225 at JPMorgan

TIPRANKS
·
Mar 05

JPMorgan Adjusts Price Target on Johnson & Johnson to $250 From $225, Maintains Neutral Rating

MT Newswires Live
·
Mar 05

J&J Has Launched J&J Direct Website to Sell Drugs Direct to U.S. Consumers

THOMSON REUTERS
·
Mar 05

Perrigo Co. PLC Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 05

Coloplast names Gavin Wood CEO effective May 1, 2026

Reuters
·
Mar 05

Should FDA Fast Track Status for Nipocalimab in Lupus Reshape Johnson & Johnson’s (JNJ) Immunology Ambitions?

Simply Wall St.
·
Mar 05

China commerce vice minister met with Johnson & Johnson VP

Reuters
·
Mar 04

China Commerce Ministry Says Chief Trade Negotiator Met With Johnson & Johnson Vp

THOMSON REUTERS
·
Mar 04

Perrigo Co. PLC Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Mar 04

Johnson & Johnson VP Corporate Controller Robert J. Decker Disposes of Common Shares

Reuters
·
Mar 04

J&J CFO Says Co Does Not Anticipate Material Impacts to Financial Performance Due to Iran Conflict - TD Cowen Conference

THOMSON REUTERS
·
Mar 04

Johnson & Johnson wins FDA Fast Track status for nipocalimab in systemic lupus erythematosus

Reuters
·
Mar 03

Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track Designation in Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
Mar 03

Johnson & Johnson price target raised to $253 from $227 at BofA

TIPRANKS
·
Mar 03

Balanced Outlook on Johnson & Johnson: Higher Oncology-Driven Estimates but Limited Upside Justify Hold Rating

TIPRANKS
·
Mar 03

Johnson & Johnson Updates Financial Calendar

Reuters
·
Mar 03

AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson

Benzinga_recent_news
·
Mar 03